• Investors
  • News
  • Subscribe
Hit enter to search or ESC to close
Cardax, Inc. | CDXI
  • About Us
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Company History
  • Astaxanthin
    • Overview
      • Astaxanthin Overview
      • History and Background
      • Safety
      • Mechanism of Action
      • Synthetic vs. Natural Astaxanthin
    • Research in Key Addressable Markets
      • Cardiovascular Disease
      • Metabolic Disease
      • Liver Disease
      • Arthritis
      • Aging
      • Coronavirus Disease 2019 (COVID-19)
    • Scientific Literature
  • Programs
    • Product Platform
    • Commercialization Strategy
    • ZanthoSyn®
    • CDX-101
    • CDX-301
    • CHASE Clinical Trial
    • Intellectual Property
  • Newsroom
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
Cardax, Inc. | CDXI

All SEC Filings

Investor Relations
Investors
  • Overview
  • News / Events
    • Press Releases
    • Media Coverage
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Profile
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
Date Form Description PDF XBRL Pages
09/30/21 D Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(a)(5) under the Act. 4
08/11/21 15-15D Notice of suspension of duty to file reports pursuant to Section 13 and 15(d) of the Act 1
08/11/21 8-K Current report filing
Documents
EX-99.1
3
08/09/21 EFFECT Notice of Effectiveness 1
08/05/21 POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing 2
07/01/21 8-K Current report filing
Documents
EX-16.1
4
05/14/21 10-Q Quarterly report pursuant to Section 13 or 15(d)
Documents
EX-31.1
EX-31.2
EX-32.1
EX-32.2
31
04/15/21 10-K Annual report pursuant to Section 13 and 15(d)
Documents
EX-10.47
EX-10.48
EX-31.1
EX-31.2
EX-32.1
EX-32.2
97
03/31/21 NT 10-K Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10-KT 2
03/10/21 RW Registration Withdrawal Request 1
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10

SEC Filings

  • All SEC Filings
  • Annual Reports
  • Quarterly Reports
  • Section 16 Filings
Subscribe to Receive Updates by E-Mail Cardax News Alerts

Recent News

  • Cardax Announces Breakthrough Longevity Results with ZanthoSyn® in NIH-Funded StudyDecember 6, 2023
  • Cardax Refocuses on ZanthoSyn® Consumer Health BusinessAugust 31, 2021
  • Cardax Voluntarily Suspends SEC Reporting ObligationsAugust 11, 2021

*These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.

© 2025 Cardax, Inc. | Disclaimer and Terms of Use | Accessibility Statement

  • About Us
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Company History
  • Astaxanthin
    • Overview
      • Astaxanthin Overview
      • History and Background
      • Safety
      • Mechanism of Action
      • Synthetic vs. Natural Astaxanthin
    • Research in Key Addressable Markets
    • Scientific Literature
  • Programs
    • Product Platform
    • Commercialization Strategy
    • ZanthoSyn®
    • CDX-101
    • CDX-301
    • CHASE Clinical Trial
    • Intellectual Property
  • Newsroom
  • Investors
    • Investor Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • Contact Us
  • Investors
  • News
  • Subscribe